Table 1.
Baseline demographics (mITT population)
| PF‐05280586 | Rituximab‐EU | Rituximab‐US | |
|---|---|---|---|
| n = 73 | n = 74 | n = 73 | |
| Gender, n (%) | |||
| Male | 14 (19.2) | 17 (23.0) | 19 (26.0) |
| Female | 59 (80.8) | 57 (77.0) | 54 (74.0) |
| Age, mean ± SD, years | 54.9 ± 11.52 | 54.9 ± 11.07 | 53.4 ± 11.87 |
| Race, n (%) | |||
| White | 56 (76.7) | 57 (77.0) | 58 (79.5) |
| Black | 2 (2.7) | 6 (8.1) | 5 (6.8) |
| Asian | 3 (4.1) | 0 (0.0) | 1 (1.4) |
| Other | 12 (16.4) | 11 (14.9) | 9 (12.3) |
| Disease duration since first diagnosis, mean ± SD, months | 153.3 ± 99.34 | 140.6 ± 98.91 | 125.0 ± 96.83 |
| Body mass index, mean ± SD, kg m–2 | 31.47 ± 8.133 | 29.76 ± 6.29 | 29.00 ± 6.74 |
mITT, modified intent‐to‐treat; SD, standard deviation.